Therapeutic effects of melatonin receptor agonists on sleep and comorbid disorders

International Journal of Molecular Sciences

Volumn 15, Issue 9, 2014, Pages 15924-15950

  Laudon, Moshe ^a   Frydman Marom, Anat ^a  

^a NEURIM PHARMACEUTICALS LTD   (Israel)

Author keywords

Insomnia comorbid; Melatonin receptors agonists; Sleep

Indexed keywords

AGOMELATINE; ATENOLOL; BENZODIAZEPINE; FLUOXETINE; MELATONIN RECEPTOR AGONIST; METOPROLOL; MIANSERIN; MIRTAZAPINE; PAROXETINE; PLACEBO; RAMELTEON; SERTRALINE; SIMVASTATIN; SPIRONOLACTONE; TASIMELTEON; TRAZODONE; VENLAFAXINE; ACETAMIDE DERIVATIVE; BENZOFURAN DERIVATIVE; CYCLOPROPANE DERIVATIVE; HYPNOTIC SEDATIVE AGENT; INDENE DERIVATIVE; MELATONIN; MELATONIN RECEPTOR;

ALZHEIMER DISEASE; ALZHEIMER DISEASE ASSESSMENT SCALE; CARDIOVASCULAR DISEASE; COMORBIDITY; DELIRIUM; DRUG EFFICACY; DRUG SAFETY; HAMILTON SCALE; HUMAN; INSOMNIA; MAJOR DEPRESSION; META ANALYSIS (TOPIC); MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; NONHUMAN; PARASOMNIA; PARKINSON DISEASE; PITTSBURGH SLEEP QUALITY INDEX; POSTTRAUMATIC STRESS DISORDER; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; REVIEW; SCHIZOPHRENIA; SLEEP DISORDER; SLEEP WAKING CYCLE; AGONISTS; ANIMAL; CLINICAL TRIAL (TOPIC); METABOLISM; NEURODEGENERATIVE DISEASES; PATHOLOGY; SLEEP DISORDERS;

ACETAMIDES; ANIMALS; BENZOFURANS; CLINICAL TRIALS AS TOPIC; CYCLOPROPANES; HUMANS; HYPNOTICS AND SEDATIVES; INDENES; MELATONIN; NEURODEGENERATIVE DISEASES; RECEPTORS, MELATONIN; SLEEP DISORDERS;

EID: 84908337994     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms150915924     Document Type: Review

References (185)

1. Reynolds, C.F., 3rd; O'Hara, R. DSM-5 sleep-wake disorders classification: Overview for use in clinical practice. Am. J. Psychiatry 2013, 170, 1099-1101.
2. Roth, T.; Roehrs, T. Insomnia: Epidemiology, characteristics, and consequences. Clin. Cornerstone 2003, 5, 5-15.
3. Roth, T. Comorbid insomnia: Current directions and future challenges. Am. J. Manag. Care 2009, 15, S6-S13.
4. Sivertsen, B.; Lallukka, T.; Salo, P.; Pallesen, S.; Hysing, M.; Krokstad, S.; Simon, O. Insomnia as a risk factor for ill health: Results from the large population-based prospective hunt study in norway. J. Sleep Res. 2014, 23, 124-132.
5. Pigeon, W.R.; Bishop, T.M.; Marcus, J.A. Advances in the management of insomnia. F1000Prime Rep. 2014, doi:10.12703/P6-48.
6. Buysse, D.J. Insomnia. JAMA 2013, 309, 706-716.
7. Reiter, R.J.; Tan, D.X.; Fuentes-Broto, L. Melatonin: A multitasking molecule. Prog. Brain Res. 2010, 181, 127-151.
8. Cajochen, C.; Krauchi, K.; Wirz-Justice, A. Role of melatonin in the regulation of human circadian rhythms and sleep. J. Neuroendocrinol. 2003, 15, 432-437.
9. Gorfine, T.; Assaf, Y.; Goshen-Gottstein, Y.; Yeshurun, Y.; Zisapel, N. Sleep-anticipating effects of melatonin in the human brain. Neuroimage 2006, 31, 410-418.
10. Sharma, M.; Palacios-Bois, J.; Schwartz, G.; Iskandar, H.; Thakur, M.; Quirion, R.; Nair, N.P. Circadian rhythms of melatonin and cortisol in aging. Biol. Psychiatry 1989, 25, 305-319.
11. Leger, D.; Laudon, M.; Zisapel, N. Nocturnal 6-sulfatoxymelatonin excretion in insomnia and its relation to the response to melatonin replacement therapy. Am. J. Med. 2004, 116, 91-95.
12. Melke, J.; Goubran Botros, H.; Chaste, P.; Betancur, C.; Nygren, G.; Anckarsater, H.; Rastam, M.; Stahlberg, O.; Gillberg, I.C.; Delorme, R.; et al. Abnormal melatonin synthesis in autism spectrum disorders. Mol. Psychiatry 2008, 13, 90-98.
13. Rossignol, D.A.; Frye, R.E. Melatonin in autism spectrum disorders: A systematic review and meta-analysis. Dev. Med. Child. Neurol. 2011, 53, 783-792.
14. Patzold, L.M.; Richdale, A.L.; Tonge, B.J. An investigation into sleep characteristics of children with autism and asperger's disorder. J. Paediatr. Child. Health 1998, 34, 528-533.
15. De Leersnyder, H.; Zisapel, N.; Laudon, M. Prolonged-release melatonin for children with neurodevelopmental disorders. Pediatr. Neurol. 2011, 45, 23-26.
16. Zisapel, N. Circadian rhythm sleep disorders: Pathophysiology and potential approaches to management. CNS Drugs 2001, 15, 311-328.
17. Pandi-Perumal, S.R.; Srinivasan, V.; Spence, D.W.; Moscovitch, A.; Hardeland, R.; Brown, G.M.; Cardinali, D.P. Ramelteon: A review of its therapeutic potential in sleep disorders. Adv. Ther. 2009, 26, 613-626.
18. Neubauer, D.N. A review of ramelteon in the treatment of sleep disorders. Neuropsychiatr. Dis. Treat. 2008, 4, 69-79.
19. Kohsaka, M.; Kanemura, T.; Taniguchi, M.; Kuwahara, H.; Mikami, A.; Kamikawa, K.; Uno, H.; Ogawa, A.; Murasaki, M.; Sugita, Y. Efficacy and tolerability of ramelteon in a double-blind, placebo-controlled, crossover study in japanese patients with chronic primary insomnia. Expert Rev. Neurother. 2011, 11, 1389-1397.
20. Hardeland, R. New approaches in the management of insomnia: Weighing the advantages of prolonged-release melatonin and synthetic melatoninergic agonists. Neuropsychiatr. Dis. Treat. 2009, 5, 341-354.
21. Hatta, K.; Kishi, Y.; Wada, K.; Takeuchi, T.; Odawara, T.; Usui, C.; Nakamura, H. Preventive effects of ramelteon on delirium: A randomized placebo-controlled trial. JAMA Psychiatry 2014, 71, 397-403.
22. Tsuda, A.; Nishimura, K.; Naganawa, E.; Otsubo, T.; Ishigooka, J. Ramelteon for the treatment of delirium in elderly patients: A consecutive case series study. Int. J. Psychiatry Med. 2014, 47, 97-104.
23. Czeisler, C.A.; Dumont, M.; Duffy, J.F.; Steinberg, J.D.; Richardson, G.S.; Brown, E.N.; Sanchez, R.; Rios, C.D.; Ronda, J.M. Association of sleep-wake habits in older people with changes in output of circadian pacemaker. Lancet 1992, 340, 933-936.
24. Haimov, I.; Laudon, M.; Zisapel, N.; Souroujon, M.; Nof, D.; Shlitner, A.; Herer, P.; Tzischinsky, O.; Lavie, P. Sleep disorders and melatonin rhythms in elderly people. BMJ 1994, 309, 167.
25. Rodenbeck, A.; Huether, G.; Ruther, E.; Hajak, G. Nocturnal melatonin secretion and its modification by treatment in patients with sleep disorders. Adv. Exp. Med. Biol. 1999, 467, 89-93.
26. Wade, A.G.; Ford, I.; Crawford, G.; McConnachie, A.; Nir, T.; Laudon, M.; Zisapel, N. Nightly treatment of primary insomnia with prolonged release melatonin for 6 months: A randomized placebo controlled trial on age and endogenous melatonin as predictors of efficacy and safety. BMC Med. 2010, 8, 51.
27. Wade, A.G.; Crawford, G.; Ford, I.; McConnachie, A.; Nir, T.; Laudon, M.; Zisapel, N. Prolonged release melatonin in the treatment of primary insomnia: Evaluation of the age cut-off for short- and long-term response. Curr. Med. Res. Opin. 2011, 27, 87-98.
28. Lemoine, P.; Zisapel, N. Prolonged-release formulation of melatonin (Circadin) for the treatment of insomnia. Expert Opin. Pharmacother. 2012, 13, 895-905.
29. Lemoine, P.; Nir, T.; Laudon, M.; Zisapel, N. Prolonged-release melatonin improves sleep quality and morning alertness in insomnia patients aged 55 years and older and has no withdrawal effects. J. Sleep Res. 2007, 16, 372-380.
30. Garfinkel, D.; Zorin, M.; Wainstein, J.; Matas, Z.; Laudon, M.; Zisapel, N. Efficacy and safety of prolonged-release melatonin in insomnia patients with diabetes: A randomized, double-blind, crossover study. Diabetes Metab. Syndr. Obes. 2011, 4, 307-313.
31. Carney, R.M.; Shelton, R.C. Agomelatine for the treatment of major depressive disorder. Expert Opin. Pharmacother. 2011, 12, 2411-2419.
32. Dolder, C.R.; Nelson, M.; Snider, M. Agomelatine treatment of major depressive disorder. Ann. Pharmacother. 2008, 42, 1822-1831.
33. Taylor, D.; Sparshatt, A.; Varma, S.; Olofinjana, O. Antidepressant efficacy of agomelatine: Meta-analysis of published and unpublished studies. BMJ 2014, 348, g1888.
34. Ambresin, G.; Gunn, J. Does agomelatine have a place in the treatment of depression? BMJ 2014, 348, g2157.
35. Sansone, R.A.; Sansone, L.A. Agomelatine: A novel antidepressant. Innov. Clin. Neurosci. 2011, 8, 10-14.
36. Kasper, S.; Hajak, G. The efficacy of agomelatine in previously-treated depressed patients. Eur. Neuropsychopharmacol. 2013, 23, 814-821.
37. 2Creceptors. Int. J. Neuropsychopharmacol. 2011, 14, 768-783.
38. Dubovsky, S.L.; Warren, C. Agomelatine, a melatonin agonist with antidepressant properties. Expert Opin. Investig. Drugs 2009, 18, 1533-1540.
39. Howland, R.H. A benefit-risk assessment of agomelatine in the treatment of major depression. Drug Saf. 2011, 34, 709-731.
40. Rajaratnam, S.M.; Polymeropoulos, M.H.; Fisher, D.M.; Roth, T.; Scott, C.; Birznieks, G.; Klerman, E.B. Melatonin agonist tasimelteon (VEC-162) for transient insomnia after sleep-time shift: Two randomized controlled multicenter trials. Lancet 2009, 373, 482-491.
41. Cardinali, D.P.; Cano, P.; Jimenez-Ortega, V.; Esquifino, A.I. Melatonin and the metabolic syndrome: Physiopathologic and therapeutical implications. Neuroendocrinology 2011, 93, 133-142.
42. Dhillon, S.; Clarke, M. Tasimelteon: First global approval. Drugs 2014, 74, 505-511.
43. Hardeland, R. Tasimelteon, a melatonin agonist for the treatment of insomnia and circadian rhythm sleep disorders. Curr. Opin. Investig. Drugs 2009, 10, 691-701.
44. Mulchahey, J.J.; Goldwater, D.R.; Zemlan, F.P. A single blind, placebo controlled, across groups dose escalation study of the safety, tolerability, pharmacokinetics and pharmacodynamics of the melatonin analog β-methyl-6-chloromelatonin. Life Sci. 2004, 75, 1843-1856.
45. Sivertsen, B.; Salo, P.; Mykletun, A.; Hysing, M.; Pallesen, S.; Krokstad, S.; Nordhus, I.H.; Overland, S. The bidirectional association between depression and insomnia: The hunt study. Psychosom. Med. 2012, 74, 758-765.
46. Jansson-Frojmark, M.; Lindblom, K. A bidirectional relationship between anxiety and depression, and insomnia? A prospective study in the general population. J. Psychosom. Res. 2008, 64, 443-449.
47. Paudel, M.L.; Taylor, B.C.; Diem, S.J.; Stone, K.L.; Ancoli-Israel, S.; Redline, S.; Ensrud, K.E. Association between depressive symptoms and sleep disturbances in community-dwelling older men. J. Am. Geriatr. Soc. 2008, 56, 1228-1235.
48. Riemann, D. Insomnia and comorbid psychiatric disorders. Sleep Med. 2007, 8, S15-S20.
49. Ohayon, M.M.; Roth, T. Place of chronic insomnia in the course of depressive and anxiety disorders. J. Psychiatr. Res. 2003, 37, 9-15.
50. Sarsour, K.; van Brunt, D.L.; Johnston, J.A.; Foley, K.A.; Morin, C.M.; Walsh, J.K. Associations of nonrestorative sleep with insomnia, depression, and daytime function. Sleep Med. 2010, 11, 965-972.
51. Pigeon, W.R.; Hegel, M.; Unutzer, J.; Fan, M.Y.; Sateia, M.J.; Lyness, J.M.; Phillips, C.; Perlis, M.L. Is insomnia a perpetuating factor for late-life depression in the impact cohort? Sleep 2008, 31, 481-488.
52. Ford, D.E.; Cooper-Patrick, L. Sleep disturbances and mood disorders: An epidemiologic perspective. Depress. Anxiety 2001, 14, 3-6.
53. Ford, D.E.; Kamerow, D.B. Epidemiologic study of sleep disturbances and psychiatric disorders. An opportunity for prevention? JAMA 1989, 262, 1479-1484.
54. Malik, S.; Kanwar, A.; Sim, L.A.; Prokop, L.J.; Wang, Z.; Benkhadra, K.; Murad, M.H. The association between sleep disturbances and suicidal behaviors in patients with psychiatric diagnoses: A systematic review and meta-analysis. Syst. Rev. 2014, doi:10.1186/2046-4053-3-18.
55. Luca, A.; Luca, M.; Calandra, C. Sleep disorders and depression: Brief review of the literature, case report, and nonpharmacologic interventions for depression. Clin. Interv. Aging 2013, 8, 1033-1039.
56. Campos Costa, I.; Nogueira Carvalho, H.; Fernandes, L. Aging, circadian rhythms and depressive disorders: A review. Am. J. Neurodegener. Dis. 2013, 2, 228-246.
57. Gaffori, O.; van Ree, J.M. Serotonin and antidepressant drugs antagonize melatonin-induced behavioural changes after injection into the nucleus accumbens of rats. Neuropharmacology 1985, 24, 237-244.
58. 2Areceptor-mediated neurotransmission: Behavioral and biochemical studies in the rat. J. Pharmacol. Exp. Ther. 1995, 273, 304-308.
59. Raghavendra, V.; Kaur, G.; Kulkarni, S.K. Anti-depressant action of melatonin in chronic forced swimming-induced behavioral despair in mice, role of peripheral benzodiazepine receptor modulation. Eur. Neuropsychopharmacol. 2000, 10, 473-481.
60. Hill, M.N.; Brotto, L.A.; Lee, T.T.; Gorzalka, B.B. Corticosterone attenuates the antidepressant-like effects elicited by melatonin in the forced swim test in both male and female rats. Prog. Neuropsychopharmacol. Biol. Psychiatry 2003, 27, 905-911.
61. Mantovani, M.; Pertile, R.; Calixto, J.B.; Santos, A.R.; Rodrigues, A.L. Melatonin exerts an antidepressant-like effect in the tail suspension test in mice: Evidence for involvement of N-methyl-D-aspartate receptors and the L-arginine-nitric oxide pathway. Neurosci. Lett. 2003, 343, 1-4.
62. Acuna Castroviejo, D.; Rosenstein, R.E.; Romeo, H.E.; Cardinali, D.P. Changes in gamma-aminobutyric acid high affinity binding to cerebral cortex membranes after pinealectomy or melatonin administration to rats. Neuroendocrinology 1986, 43, 24-31.
63. Niles, L.P.; Pickering, D.S.; Arciszewski, M.A. Effects of chronic melatonin administration on gaba and diazepam binding in rat brain. J. Neural Transm. 1987, 70, 117-124.
64. Rosenstein, R.E.; Cardinali, D.P. Melatonin increases in vivo gaba accumulation in rat hypothalamus, cerebellum, cerebral cortex and pineal gland. Brain Res. 1986, 398, 403-406.
65. Rosenstein, R.E.; Estevez, A.G.; Cardinali, D.P. Time-dependent effect of melatonin on glutamic acid decarboxylase activity and CI influx in rat hypothalamus. J. Neuroendocrinol. 1989, 1, 443-447.
66. Barden, N.; Shink, E.; Labbe, M.; Vacher, R.; Rochford, J.; Mocaer, E. Antidepressant action of agomelatine (S 20098) in a transgenic mouse model. Prog. Neuropsychopharmacol. Biol. Psychiatry 2005, 29, 908-916.
67. Bertaina-Anglade, V.; la Rochelle, C.D.; Boyer, P.A.; Mocaer, E. Antidepressant-like effects of agomelatine (S 20098) in the learned helplessness model. Behav. Pharmacol. 2006, 17, 703-713.
68. Bourin, M.; Mocaer, E.; Porsolt, R. Antidepressant-like activity of S 20098 (agomelatine) in the forced swimming test in rodents: Involvement of melatonin and serotonin receptors. J. Psychiatry Neurosci. 2004, 29, 126-133.
69. Pinder, R.M. The pharmacologic rationale for the clinical use of antidepressants. J. Clin. Psychiatry 1997, 58, 501-508.
70. 2Areceptor-mediated behaviors: Attenuation by melatonin. Physiol. Behav. 1999, 67, 439-442.
71. 3H]serotonin release in the rat hippocampus: Effects of circadian rhythm. J. Neuroendocrinol. 2002, 14, 194-199.
72. Tian, S.W.; Laudon, M.; Han, L.; Gao, J.; Huang, F.L.; Yang, Y.F.; Deng, H.F. Antidepressant- and anxiolytic effects of the novel melatonin agonist Neu-P11 in rodent models. Acta Pharmacol. Sin. 2010, 31, 775-783.
73. Suresh Kumar, P.N.; Andrade, C.; Bhakta, S.G.; Singh, N.M. Melatonin in schizophrenic outpatients with insomnia: A double-blind, placebo-controlled study. J. Clin. Psychiatry 2007, 68, 237-241.
74. Shamir, E.; Laudon, M.; Barak, Y.; Anis, Y.; Rotenberg, V.; Elizur, A.; Zisapel, N. Melatonin improves sleep quality of patients with chronic schizophrenia. J. Clin. Psychiatry 2000, 61, 373-377.
75. Dolberg, O.T.; Hirschmann, S.; Grunhaus, L. Melatonin for the treatment of sleep disturbances in major depressive disorder. Am. J. Psychiatry 1998, 155, 1119-1121.
76. Dalton, E.J.; Rotondi, D.; Levitan, R.D.; Kennedy, S.H.; Brown, G.M. Use of slow-release melatonin in treatment-resistant depression. J. Psychiatry Neurosci. 2000, 25, 48-52.
77. Quera Salva, M.A.; Vanier, B.; Laredo, J.; Hartley, S.; Chapotot, F.; Moulin, C.; Lofaso, F.; Guilleminault, C. Major depressive disorder, sleep eeg and agomelatine: An open-label study. Int. J. Neuropsychopharmacol. 2007, 10, 691-696.
78. Lemoine, P.; Guilleminault, C.; Alvarez, E. Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: Randomized, double-blind comparison with venlafaxine. J. Clin. Psychiatry 2007, 68, 1723-1732.
79. Kasper, S.; Hajak, G.; Wulff, K.; Hoogendijk, W.J.; Montejo, A.L.; Smeraldi, E.; Rybakowski, J.K.; Quera-Salva, M.A.; Wirz-Justice, A.M.; Picarel-Blanchot, F.; et al. Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: A randomized, double-blind comparison with sertraline. J. Clin. Psychiatry 2010, 71, 109-120.
80. Gross, P.K.; Nourse, R.; Wasser, T.E. Ramelteon for insomnia symptoms in a community sample of adults with generalized anxiety disorder: An open label study. J. Clin. Sleep Med. 2009, 5, 28-33.
81. McElroy, S.L.; Winstanley, E.L.; Martens, B.; Patel, N.C.; Mori, N.; Moeller, D.; McCoy, J.; Keck, P.E., Jr. A randomized, placebo-controlled study of adjunctive ramelteon in ambulatory bipolar I disorder with manic symptoms and sleep disturbance. Int. Clin. Psychopharmacol. 2011, 26, 48-53.
82. Norris, E.R.; Karen, B.; Correll, J.R.; Zemanek, K.J.; Lerman, J.; Primelo, R.A.; Kaufmann, M.W. A double-blind, randomized, placebo-controlled trial of adjunctive ramelteon for the treatment of insomnia and mood stability in patients with euthymic bipolar disorder. J. Affect. Disord. 2013, 144, 141-147.
83. Zhang, T.; Wei, G.; Yan, Z.; Ding, M.; Li, C.; Ding, H.; Xu, S. Quantitative assessment of Parkinson's disease deficits. Chin. Med. J. 1999, 112, 812-815.
84. Maguire-Zeiss, K.A.; Federoff, H.J. Future directions for immune modulation in neurodegenerative disorders: Focus on Parkinson's disease. J. Neural Transm. 2010, 117, 1019-1025.
85. Tansey, M.G.; McCoy, M.K.; Frank-Cannon, T.C. Neuroinflammatory mechanisms in Parkinson's disease: Potential environmental triggers, pathways, and targets for early therapeutic intervention. Exp. Neurol. 2007, 208, 1-25.
86. Provini, F.; Lombardi, C.; Lugaresi, E. Insomnia in neurological diseases. Semin Neurol. 2005, 25, 81-89.
87. Rothman, S.M.; Mattson, M.P. Sleep disturbances in Alzheimer's and Parkinson's diseases. Neuromol. Med. 2012, 14, 194-204.
88. Ju, Y.E.; Lucey, B.P.; Holtzman, D.M. Sleep and Alzheimer disease pathology-A bidirectional relationship. Nat. Rev. Neurol. 2014, 10, 115-119.
89. Lim, A.S.; Kowgier, M.; Yu, L.; Buchman, A.S.; Bennett, D.A. Sleep fragmentation and the risk of incident Alzheimer's disease and cognitive decline in older persons. Sleep 2013, 36, 1027-1032.
90. Miyata, S.; Noda, A.; Iwamoto, K.; Kawano, N.; Okuda, M.; Ozaki, N. Poor sleep quality impairs cognitive performance in older adults. J. Sleep Res. 2013, 22, 535-541.
91. Spira, A.P.; Gamaldo, A.A.; An, Y.; Wu, M.N.; Simonsick, E.M.; Bilgel, M.; Zhou, Y.; Wong, D.F.; Ferrucci, L.; Resnick, S.M. Self-reported sleep and β-amyloid deposition in community-dwelling older adults. JAMA Neurol. 2013, 70, 1537-1543.
92. Ju, Y.E.; McLeland, J.S.; Toedebusch, C.D.; Xiong, C.; Fagan, A.M.; Duntley, S.P.; Morris, J.C.; Holtzman, D.M. Sleep quality and preclinical Alzheimer disease. JAMA Neurol. 2013, 70, 587-593.
93. Dauvilliers, Y. Insomnia in patients with neurodegenerative conditions. Sleep Med. 2007, 8, S27-S34.
94. Adler, C.H. Nonmotor complications in Parkinson's disease. Mov. Disord. 2005, 20, S23-S29.
95. Adler, C.H.; Thorpy, M.J. Sleep issues in Parkinson's disease. Neurology 2005, 64, S12-S20.
96. Iranzo de Riquer, A.; Bergareche, A.; Campos, V. Sleep disorders in Parkinson disease. Neurologist 2011, 17, S38-S42.
97. Schulte, E.C.; Winkelmann, J. When Parkinson's disease patients go to sleep: Specific sleep disturbances related to Parkinson's disease. J. Neurol. 2011, 258, S328-S335.
98. Stocchi, F.; Barbato, L.; Nordera, G.; Berardelli, A.; Ruggieri, S. Sleep disorders in Parkinson's disease. J. Neurol. 1998, 245, S15-S18.
99. Barber, A.; Dashtipour, K. Sleep disturbances in Parkinson's disease with emphasis on rapid eye movement sleep behavior disorder. Int. J. Neurosci. 2012, 122, 407-412.
100. Comella, C.L. Sleep disturbances and excessive daytime sleepiness in Parkinson disease: An overview. J. Neural Transm. Suppl. 2006, 349-355.
101. Rosales-Corral, S.A.; Lopez-Armas, G.; Cruz-Ramos, J.; Melnikov, V.G.; Tan, D.X.; Manchester, L.C.; Munoz, R.; Reiter, R.J. Alterations in lipid levels of mitochondrial membranes induced by amyloid-β: A protective role of melatonin. Int. J. Alzheimers Dis. 2012, 2012, 459806.
102. Hoppe, J.B.; Frozza, R.L.; Horn, A.P.; Comiran, R.A.; Bernardi, A.; Campos, M.M.; Battastini, A.M.; Salbego, C. Amyloid-β neurotoxicity in organotypic culture is attenuated by melatonin: Involvement of GSK-3β, tau and neuroinflammation. J. Pineal Res. 2010, 48, 230-238.
103. Olcese, J.M.; Cao, C.; Mori, T.; Mamcarz, M.B.; Maxwell, A.; Runfeldt, M.J.; Wang, L.; Zhang, C.; Lin, X.; Zhang, G.; et al. Protection against cognitive deficits and markers of neurodegeneration by long-term oral administration of melatonin in a transgenic model of Alzheimer disease. J. Pineal Res. 2009, 47, 82-96.
104. Wang, J.Z.; Wang, Z.F. Role of melatonin in Alzheimer-like neurodegeneration. Acta Pharmacol. Sin. 2006, 27, 41-49.
105. Liu, X.J.; Yuan, L.; Yang, D.; Han, W.N.; Li, Q.S.; Yang, W.; Liu, Q.S.; Qi, J.S. Melatonin protects against amyloid-β-induced impairments of hippocampal ltp and spatial learning in rats. Synapse 2013, 67, 626-636.
106. Dabbeni-Sala, F.; di Santo, S.; Franceschini, D.; Skaper, S.D.; Giusti, P. Melatonin protects against 6-OHDA-induced neurotoxicity in rats: A role for mitochondrial complex I activity. Faseb J. 2001, 15, 164-170.
107. Naskar, A.; Manivasagam, T.; Chakraborty, J.; Singh, R.; Thomas, B.; Dhanasekaran, M.; Mohanakumar, K.P. Melatonin synergizes with low doses of L-DOPA to improve dendritic spine density in the mouse striatum in experimental Parkinsonism. J. Pineal Res. 2013, 55, 304-312.
108. Acuna-Castroviejo, D.; Coto-Montes, A.; Gaia Monti, M.; Ortiz, G.G.; Reiter, R.J. Melatonin is protective against MPTP-induced striatal and hippocampal lesions. Life Sci. 1997, 60, PL23-PL29.
109. Antolin, I.; Mayo, J.C.; Sainz, R.M.; del Brio Mde, L.; Herrera, F.; Martin, V.; Rodriguez, C. Protective effect of melatonin in a chronic experimental model of Parkinson's disease. Brain Res. 2002, 943, 163-173.
110. Lin, L.; Huang, Q.X.; Yang, S.S.; Chu, J.; Wang, J.Z.; Tian, Q. Melatonin in Alzheimer's disease. Int. J. Mol. Sci. 2013, 14, 14575-14593.
111. Srinivasan, V.; Kaur, C.; Pandi-Perumal, S.; Brown, G.M.; Cardinali, D.P. Melatonin and its agonist ramelteon in Alzheimer's disease: Possible therapeutic value. Int. J. Alzheimers Dis. 2010, 2011, 741974.
112. Mishima, K.; Tozawa, T.; Satoh, K.; Matsumoto, Y.; Hishikawa, Y.; Okawa, M. Melatonin secretion rhythm disorders in patients with senile dementia of Alzheimer's type with disturbed sleep-waking. Biol. Psychiatry 1999, 45, 417-421.
113. Zhou, J.N.; Liu, R.Y.; Kamphorst, W.; Hofman, M.A.; Swaab, D.F. Early neuropathological Alzheimer's changes in aged individuals are accompanied by decreased cerebrospinal fluid melatonin levels. J. Pineal Res. 2003, 35, 125-130.
114. Liu, R.Y.; Zhou, J.N.; van Heerikhuize, J.; Hofman, M.A.; Swaab, D.F. Decreased melatonin levels in postmortem cerebrospinal fluid in relation to aging, Alzheimer's disease, and apolipoprotein E-ε4/4 genotype. J. Clin. Endocrinol. Metab. 1999, 84, 323-327.
115. Asayama, K.; Yamadera, H.; Ito, T.; Suzuki, H.; Kudo, Y.; Endo, S. Double blind study of melatonin effects on the sleep-wake rhythm, cognitive and non-cognitive functions in Alzheimer type dementia. J. Nippon Med. Sch. 2003, 70, 334-341.
116. Singer, C.; Tractenberg, R.E.; Kaye, J.; Schafer, K.; Gamst, A.; Grundman, M.; Thomas, R.; Thal, L.J. A multicenter, placebo-controlled trial of melatonin for sleep disturbance in Alzheimer's disease. Sleep 2003, 26, 893-901.
117. Dowling, G.A.; Burr, R.L.; van Someren, E.J.; Hubbard, E.M.; Luxenberg, J.S.; Mastick, J.; Cooper, B.A. Melatonin and bright-light treatment for rest-activity disruption in institutionalized patients with Alzheimer's disease. J. Am. Geriatr. Soc. 2008, 56, 239-246.
118. Wade, A.G.; Farmer, M.; Harari, G.; Fund, N.; Laudon, M.; Nir, T.; Frydman-Marom, A.; Zisapel, N. Add-on prolonged-release melatonin for cognitive function and sleep in mild to moderate Alzheimer's disease: A 6-month, randomized, placebo-controlled, multicenter trial. Clin. Interv. Aging 2014, 9, 947-961.
119. Gehrman, P.R.; Connor, D.J.; Martin, J.L.; Shochat, T.; Corey-Bloom, J.; Ancoli-Israel, S. Melatonin fails to improve sleep or agitation in double-blind randomized placebo-controlled trial of institutionalized patients with Alzheimer disease. Am. J. Geriatr. Psychiatry 2009, 17, 166-169.
120. Serfaty, M.; Kennell-Webb, S.; Warner, J.; Blizard, R.; Raven, P. Double blind randomised placebo controlled trial of low dose melatonin for sleep disorders in dementia. Int. J. Geriatr. Psychiatry 2002, 17, 1120-1127.
121. Furio, A.M.; Brusco, L.I.; Cardinali, D.P. Possible therapeutic value of melatonin in mild cognitive impairment: A retrospective study. J. Pineal Res. 2007, 43, 404-409.
122. Cardinali, D.P.; Vigo, D.E.; Olivar, N.; Vidal, M.F.; Furio, A.M.; Brusco, L.I. Therapeutic application of melatonin in mild cognitive impairment. Am. J. Neurodegener. Dis. 2012, 1, 280-291.
123. Willis, G.L. The role of ML-23 and other melatonin analogues in the treatment and management of Parkinson's disease. Drug News Perspect. 2005, 18, 437-444.
124. Willis, G.L.; Armstrong, S.M. A therapeutic role for melatonin antagonism in experimental models of Parkinson's disease. Physiol. Behav. 1999, 66, 785-795.
125. Adi, N.; Mash, D.C.; Ali, Y.; Singer, C.; Shehadeh, L.; Papapetropoulos, S. Melatonin MT1 and MT2 receptor expression in Parkinson's disease. Med. Sci. Monit. 2010, 16, BR61-BR67.
126. Bolitho, S.J.; Naismith, S.L.; Rajaratnam, S.M.; Grunstein, R.R.; Hodges, J.R.; Terpening, Z.; Rogers, N.; Lewis, S.J. Disturbances in melatonin secretion and circadian sleep-wake regulation in Parkinson disease. Sleep Med. 2014, 15, 342-347.
127. Bordet, R.; Devos, D.; Brique, S.; Touitou, Y.; Guieu, J.D.; Libersa, C.; Destee, A. Study of circadian melatonin secretion pattern at different stages of Parkinson's disease. Clin. Neuropharmacol. 2003, 26, 65-72.
128. Dowling, G.A.; Mastick, J.; Colling, E.; Carter, J.H.; Singer, C.M.; Aminoff, M.J. Melatonin for sleep disturbances in Parkinson's disease. Sleep Med. 2005, 6, 459-466.
129. Srinivasan, V.; Cardinali, D.P.; Srinivasan, U.S.; Kaur, C.; Brown, G.M.; Spence, D.W.; Hardeland, R.; Pandi-Perumal, S.R. Therapeutic potential of melatonin and its analogs in Parkinson's disease: Focus on sleep and neuroprotection. Ther. Adv. Neurol. Disord. 2011, 4, 297-317.
130. Medeiros, C.A.; Carvalhedo de Bruin, P.F.; Lopes, L.A.; Magalhaes, M.C.; de Lourdes Seabra, M.; de Bruin, V.M. Effect of exogenous melatonin on sleep and motor dysfunction in Parkinson's disease-A randomized, double blind, placebo-controlled study. J. Neurol. 2007, 254, 459-464.
131. Litvinenko, I.V.; Krasakov, I.V.; Tikhomirova, O.V. Sleep disorders in Parkinson's disease without dementia: A comparative randomized controlled study of melatonin and clonazepam. Zh Nevrol. Psikhiatr. Im. S. S. Korsak. 2012, 112, 26-30.
132. Nomura, T.; Kawase, S.; Watanabe, Y.; Nakashima, K. Use of ramelteon for the treatment of secondary rem sleep behavior disorder. Intern. Med. 2013, 52, 2123-2126.
133. Egan, B.M.; Zhao, Y.; Axon, R.N. US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. JAMA 2010, 303, 2043-2050.
134. Wolf-Maier, K.; Cooper, R.S.; Banegas, J.R.; Giampaoli, S.; Hense, H.W.; Joffres, M.; Kastarinen, M.; Poulter, N.; Primatesta, P.; Rodriguez-Artalejo, F.; et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. BMJ Open 2003, 289, 2363-2369.
135. Lanfranchi, P.A.; Pennestri, M.H.; Fradette, L.; Dumont, M.; Morin, C.M.; Montplaisir, J. Nighttime blood pressure in normotensive subjects with chronic insomnia: Implications for cardiovascular risk. Sleep 2009, 32, 760-766.
136. Gangwisch, J.E.; Malaspina, D.; Posner, K.; Babiss, L.A.; Heymsfield, S.B.; Turner, J.B.; Zammit, G.K.; Pickering, T.G. Insomnia and sleep duration as mediators of the relationship between depression and hypertension incidence. Am. J. Hypertens. 2010, 23, 62-69.
137. Fung, M.M.; Peters, K.; Redline, S.; Ziegler, M.G.; Ancoli-Israel, S.; Barrett-Connor, E.; Stone, K.L. Decreased slow wave sleep increases risk of developing hypertension in elderly men. Hypertension 2011, 58, 596-603.
138. Hermida, R.C.; Ayala, D.E.; Mojon, A.; Fernandez, J.R. Decreasing sleep-time blood pressure determined by ambulatory monitoring reduces cardiovascular risk. J. Am. Coll. Cardiol. 2011, 58, 1165-1173.
139. Hoevenaar-Blom, M.P.; Spijkerman, A.M.; Kromhout, D.; van den Berg, J.F.; Verschuren, W.M. Sleep duration and sleep quality in relation to 12-year cardiovascular disease incidence: The morgen study. Sleep 2011, 34, 1487-1492.
140. Yano, Y.; Kario, K. Nocturnal blood pressure, morning blood pressure surge, and cerebrovascular events. Curr. Hypertens. Rep. 2012, 14, 219-227.
141. Favero, G.; Rodella, L.F.; Reiter, R.J.; Rezzani, R. Melatonin and its atheroprotective effects: A review. Mol. Cell Endocrinol. 2014, 382, 926-937.
142. Zanoboni, A.; Forni, A.; Zanoboni-Muciaccia, W.; Zanussi, C. Effect of pinealectomy on arterial blood pressure and food and water intake in the rat. J. Endocrinol. Investig. 1978, 1, 125-130.
143. Simko, F.; Pechanova, O.; Pelouch, V.; Krajcirovicova, K.; Celec, P.; Palffy, R.; Bednarova, K.; Vrankova, S.; Adamcova, M.; Paulis, L. Continuous light and L-NAME-induced left ventricular remodelling: Different protection with melatonin and captopril. J. Hypertens. 2010, 28, S13-S18.
144. Sahna, E.; Acet, A.; Ozer, M.K.; Olmez, E. Myocardial ischemia-reperfusion in rats: Reduction of infarct size by either supplemental physiological or pharmacological doses of melatonin. J. Pineal Res. 2002, 33, 234-238.
145. Vazan, R.; Janega, P.; Hojna, S.; Zicha, J.; Simko, F.; Pechanova, O.; Styk, J.; Paulis, L. The effect of continuous light exposure of rats on cardiac response to ischemia-reperfusion and no-synthase activity. Physiol. Res. 2007, 56, S63-S69.
146. Tain, Y.L.; Huang, L.T.; Lin, I.C.; Lau, Y.T.; Lin, C.Y. Melatonin prevents hypertension and increased asymmetric dimethylarginine in young spontaneous hypertensive rats. J. Pineal Res. 2010, 49, 390-398.
147. Pechanova, O.; Zicha, J.; Paulis, L.; Zenebe, W.; Dobesova, Z.; Kojsova, S.; Jendekova, L.; Sladkova, M.; Dovinova, I.; Simko, F.; et al. The effect of N-acetylcysteine and melatonin in adult spontaneously hypertensive rats with established hypertension. Eur. J. Pharmacol. 2007, 561, 129-136.
148. Holmes, S.W.; Sugden, D. Proceedings: The effect of melatonin on pinealectomy-induced hypertension in the rat. Br. J. Pharmacol. 1976, 56, 360P-361P.
149. Simko, F.; Pechanova, O.; Pelouch, V.; Krajcirovicova, K.; Mullerova, M.; Bednarova, K.; Adamcova, M.; Paulis, L. Effect of melatonin, captopril, spironolactone and simvastatin on blood pressure and left ventricular remodelling in spontaneously hypertensive rats. J. Hypertens. Suppl. 2009, 27, S5-S10.
150. Forman, J.P.; Curhan, G.C.; Schernhammer, E.S. Urinary melatonin and risk of incident hypertension among young women. J. Hypertens. 2010, 28, 446-451.
151. Jonas, M.; Garfinkel, D.; Zisapel, N.; Laudon, M.; Grossman, E. Impaired nocturnal melatonin secretion in non-dipper hypertensive patients. Blood Press 2003, 12, 19-24.
152. Zeman, M.; Dulkova, K.; Bada, V.; Herichova, I. Plasma melatonin concentrations in hypertensive patients with the dipping and non-dipping blood pressure profile. Life Sci. 2005, 76, 1795-1803.
153. Brugger, P.; Marktl, W.; Herold, M. Impaired nocturnal secretion of melatonin in coronary heart disease. Lancet 1995, 345, 1408.
154. Sakotnik, A.; Liebmann, P.M.; Stoschitzky, K.; Lercher, P.; Schauenstein, K.; Klein, W.; Eber, B. Decreased melatonin synthesis in patients with coronary artery disease. Eur. Heart J. 1999, 20, 1314-1317.
155. Scheer, F.A.; Morris, C.J.; Garcia, J.I.; Smales, C.; Kelly, E.E.; Marks, J.; Malhotra, A.; Shea, S.A. Repeated melatonin supplementation improves sleep in hypertensive patients treated with β-blockers: A randomized controlled trial. Sleep 2012, 35, 1395-1402.
156. Sewerynek, E. Melatonin and the cardiovascular system. Neuro Endocrinol. Lett. 2002, 23, 79-83.
157. Cagnacci, A.; Arangino, S.; Angiolucci, M.; Maschio, E.; Longu, G.; Melis, G.B. Potentially beneficial cardiovascular effects of melatonin administration in women. J. Pineal Res. 1997, 22, 16-19.
158. Arangino, S.; Cagnacci, A.; Angiolucci, M.; Vacca, A.M.; Longu, G.; Volpe, A.; Melis, G.B. Effects of melatonin on vascular reactivity, catecholamine levels, and blood pressure in healthy men. Am. J. Cardiol. 1999, 83, 1417-1419.
159. Cagnacci, A.; Arangino, S.; Angiolucci, M.; Maschio, E.; Melis, G.B. Influences of melatonin administration on the circulation of women. Am. J. Physiol. 1998, 274, R335-R338.
160. Lemoine, P.; Wade, A.G.; Katz, A.; Nir, T.; Zisapel, N. Efficacy and safety of prolonged-release melatonin for insomnia in middle-aged and elderly patients with hypertension: A combined analysis of controlled clinical trials. Integr. Blood Press Control 2012, 5, 9-17.
161. Grossman, E.; Laudon, M.; Yalcin, R.; Zengil, H.; Peleg, E.; Sharabi, Y.; Kamari, Y.; Shen-Orr, Z.; Zisapel, N. Melatonin reduces night blood pressure in patients with nocturnal hypertension. Am. J. Med. 2006, 119, 898-902.
162. Grossman, E.; Laudon, M.; Zisapel, N. Effect of melatonin on nocturnal blood pressure: Meta-analysis of randomized controlled trials. Vasc. Health Risk Manag. 2011, 7, 577-584.
163. Lusardi, P.; Piazza, E.; Fogari, R. Cardiovascular effects of melatonin in hypertensive patients well controlled by nifedipine: A 24-h study. Br. J. Clin. Pharmacol. 2000, 49, 423-427.
164. Hiromasa, S. A new strategy of treatment of insomnia in the field of cardiology-Potential of ramelteon. Nihon Rinsho 2013, 71, 181-187.
165. Narayan, K.M.; Gregg, E.W.; Fagot-Campagna, A.; Engelgau, M.M.; Vinicor, F. Diabetes-A common, growing, serious, costly, and potentially preventable public health problem. Diabetes Res. Clin. Pract. 2000, 50, S77-S84.
166. Knutson, K.L.; van Cauter, E.; Zee, P.; Liu, K.; Lauderdale, D.S. Cross-sectional associations between measures of sleep and markers of glucose metabolism among subjects with and without diabetes: The coronary artery risk development in young adults (CARDIA) sleep study. Diabetes Care 2011, 34, 1171-1176.
167. Barone, M.T.; Menna-Barreto, L. Diabetes and sleep: A complex cause-and-effect relationship. Diabetes Res. Clin. Pract. 2011, 91, 129-137.
168. Chasens, E.R. Understanding sleep in persons with diabetes. Diabetes Educ. 2007, 33, 435-436, 438, 441.
169. Eriksson, A.K.; Ekbom, A.; Granath, F.; Hilding, A.; Efendic, S.; Ostenson, C.G. Psychological distress and risk of pre-diabetes and type 2 diabetes in a prospective study of swedish middle-aged men and women. Diabet. Med. 2008, 25, 834-842.
170. Tam, C.H.; Ho, J.S.; Wang, Y.; Lee, H.M.; Lam, V.K.; Germer, S.; Martin, M.; So, W.Y.; Ma, R.C.; Chan, J.C.; et al. Common polymorphisms in MTNR1B, G6PC2 and GCK are associated with increased fasting plasma glucose and impaired β-cell function in Chinese subjects. PLoS One 2010, 5, e11428.
171. Mussig, K.; Staiger, H.; Machicao, F.; Haring, H.U.; Fritsche, A. Genetic variants in MTNR1B affecting insulin secretion. Ann. Med. 2010, 42, 387-393.
172. Prokopenko, I.; Langenberg, C.; Florez, J.C.; Saxena, R.; Soranzo, N.; Thorleifsson, G.; Loos, R.J.; Manning, A.K.; Jackson, A.U.; Aulchenko, Y.; et al. Variants in MTNR1B influence fasting glucose levels. Nat. Genet. 2009, 41, 77-81.
173. O'Brien, I.A.; Lewin, I.G.; O'Hare, J.P.; Arendt, J.; Corrall, R.J. Abnormal circadian rhythm of melatonin in diabetic autonomic neuropathy. Clin. Endocrinol. 1986, 24, 359-364.
174. Sandyk, R.; Anastasiadis, P.G.; Anninos, P.A.; Tsagas, N. Is the pineal gland involved in the pathogenesis of endometrial carcinoma. Int. J. Neurosci. 1992, 62, 89-96.
175. Zisapel, N. Sleep and sleep disturbances: Biological basis and clinical implications. Cell Mol. Life Sci. 2007, 64, 1174-1186.
176. Nishida, S. Metabolic effects of melatonin on oxidative stress and diabetes mellitus. Endocrine 2005, 27, 131-136.
177. Robeva, R.; Kirilov, G.; Tomova, A.; Kumanov, P. Melatonin-insulin interactions in patients with metabolic syndrome. J. Pineal Res. 2008, 44, 52-56.
178. Peschke, E. Melatonin, endocrine pancreas and diabetes. J. Pineal Res. 2008, 44, 26-40.
179. Radziuk, J.; Pye, S. Diurnal rhythm in endogenous glucose production is a major contributor to fasting hyperglycaemia in type 2 diabetes. Suprachiasmatic deficit or limit cycle behaviour? Diabetologia 2006, 49, 1619-1628.
180. Vinogradova, I.; Anisimov, V. Melatonin prevents the development of the metabolic syndrome in male rats exposed to different light/dark regimens. Biogerontology 2013, 14, 401-409.
181. Hatzis, G.; Ziakas, P.; Kavantzas, N.; Triantafyllou, A.; Sigalas, P.; Andreadou, I.; Ioannidis, K.; Chatzis, S.; Filis, K.; Papalampros, A.; et al. Melatonin attenuates high fat diet-induced fatty liver disease in rats. World J. Hepatol. 2013, 5, 160-169.
182. Cardinali, D.P.; Bernasconi, P.A.; Reynoso, R.; Toso, C.F.; Scacchi, P. Melatonin may curtail the metabolic syndrome: Studies on initial and fully established fructose-induced metabolic syndrome in rats. Int. J. Mol. Sci. 2013, 14, 2502-2514.
183. Shatilo, V.B.; Bondarenko, E.V.; Antoniuk-Shcheglova, I.A. Metabolic disorders in elderly patients with hypertension and their correction with melatonin. Adv. Gerontol. 2012, 25, 84-89.
184. Kozirog, M.; Poliwczak, A.R.; Duchnowicz, P.; Koter-Michalak, M.; Sikora, J.; Broncel, M. Melatonin treatment improves blood pressure, lipid profile, and parameters of oxidative stress in patients with metabolic syndrome. J. Pineal Res. 2011, 50, 261-266.
185. Danilenko, K.; Ragino, Y. Melatonin and its use in atherosclerosis and dyslipidemia. ChronoPhysiol. Ther. 2013, 2013, 15-22.